LTGO — Latigo Biotherapeutics Inc.

LTGO closed at $15.26 (+1.60%) on Oct 26, 2026. Recent offering filing (S-1MEF, Aug 2026). Float: 50.1M shares. Latest SEC filing: SCHEDULE 13G on Aug 18, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for LTGO in the TickerWise workspace.

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

Company profile

• Sector: Healthcare
• Industry: Medical - Pharmaceuticals
• Country: US
• Exchange: NASDAQ
• Website: http://www.latigobio.com

Latest SEC filings for LTGO

• 2026-08-18SCHEDULE 13G
• 2026-08-17SCHEDULE 13G
• 2026-08-17SCHEDULE 13D
• 2026-08-123
• 2026-08-10S-8
• 2026-08-073
• 2026-08-073
• 2026-08-073
• 2026-08-073
• 2026-08-073

Related companies

• ONC — BeOne Medicines Ltd.
• LQDA — Liquidia Corporation
• DFTX — Definium Therapeutics, Inc.
• AVLN — Avalyn Pharma Inc. Common Stock
• LFMDP — LifeMD, Inc.
• CGEM — Cullinan Therapeutics, Inc.
• CUVL — Clinuvel Pharmaceuticals Ltd.
• ETRA — Electra Therapeutics Inc.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.